Pharvaris Unveils $175 Million Public Offering
Pharvaris N.V. (Nasdaq: PHVS), a biopharmaceutical leader specializing in the development of innovative oral bradykinin B2 receptor antagonists, has recently announced an upsized public offering aimed at raising $175 million. This move is pivotal in bolstering their efforts in addressing unmet needs in treating bradykinin-mediated diseases, such as hereditary angioedema (HAE) and acquired angioedema.
Details of the Offering
The company’s offering includes 8,250,000 ordinary shares priced at $20.00 each. Moreover, there are pre-funded warrants available for purchase, with up to 500,000 ordinary shares priced at $19.99 each. Notably, these offerings will be entirely sold by Pharvaris.
Additional Share Options
Pharvaris is also granting underwriters a 30-day option to purchase up to 1,312,500 additional ordinary shares at the public offering price, further extending their capital-raising efforts. Before accounting for the exercise of this option, the company expects gross proceeds to reach approximately $175 million.
Significance of the Offering
This public offering is expected to play a crucial role in funding Pharvaris’ ongoing clinical programs, particularly their pivotal Phase 3 studies evaluating deucrictibant for the prevention and treatment of angioedema attacks. With encouraging results from Phase 2 trials, the company is well-positioned to move forward with these crucial developments.
Clinical Advancements
Pharvaris aims to bring injectable-like efficacy with the convenience of oral therapies for those affected by bradykinin-mediated angioedema. Their lead candidate, deucrictibant, has shown promise in both prophylactic and on-demand patient scenarios, giving hope to many patients awaiting innovative treatments.
Engagement of Underwriters
In this offering, several prominent financial institutions are acting as joint book-running managers including Morgan Stanley, Leerink Partners, Cantor Fitzgerald, Oppenheimer & Co., and Van Lanschot Kempen. Their involvement adds credibility to the offering and reassures potential investors about the pathway ahead.
How to Obtain More Information
Investors eager to learn more about this offering can access details through the final prospectus supplement, which will be available as part of their registration with the U.S. Securities and Exchange Commission (SEC). While copies can be obtained directly from the managing underwriters, regulatory insights can also be accessed via the SEC’s official website.
About Pharvaris N.V.
Pharvaris is committed to addressing serious medical conditions through its groundbreaking research and development. The company's focus extends past mere innovation; it seeks to elevate the quality of life for individuals suffering from bradykinin-mediated disorders. With a dedicated team and robust pipeline, Pharvaris exemplifies the future of biopharmaceutical advancements.
Frequently Asked Questions
What is the amount Pharvaris aims to raise through this offering?
Pharvaris is aiming to raise $175 million through this public offering.
What are pre-funded warrants offered in this context?
Pre-funded warrants allow investors to purchase ordinary shares at a price slightly below the public offering price, providing immediate investment options for potential backers.
Which institutions are involved in this public offering?
Prominent financial institutions include Morgan Stanley, Leerink Partners, Cantor Fitzgerald, Oppenheimer & Co., and Van Lanschot Kempen, who are serving as joint book-running managers.
What is Pharvaris's main goal with this funding?
The primary objective is to support ongoing clinical development for their leading product, deucrictibant, focusing on its effectiveness in treating bradykinin-mediated diseases.
How can I find more information about Pharvaris?
Additional information can be accessed through the company’s final prospectus supplement and their filings available on the SEC’s website.
